Product
IGSC
1 clinical trial
1 indication
Indication
Primary ImmunodeficiencyClinical trial
A Multi-center, Single-Sequence, Open-label Study to Evaluate IGSC 20% Biweekly Dosing in Treatment-Experienced Subjects and Loading/Maintenance Dosing in Treatment-Naïve Subjects With Primary ImmunodeficiencyStatus: Completed, Estimated PCD: 2022-07-18